Transplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed the high expression of endostatin in endostatin-lentivirus-EPCs. The neovascularization leakage area and the number of preretinal neovascular cell nuclei were significantly decreased in the endostatin-lentivirus and endostatin-lentivirus-EPC groups, and the effects of these two treatments on inhibiting retinal neovascularization were almost the same. These two groups also showed the greater retinal distribution of endostatin. Intravitreal injections of endostatin-lentivirus-EPCs inhibited retinal neovascularization, vascular endothelial growth factor (VEGF) and CD31 expression, and increased endostatin expression in vivo. Endostatin-lentivirus-EPCs targeted and prevented pathologic retinal neovascularization. Gene-combined EPCs represent a potential new therapeutic agent for the treatment of neovascular eye diseases.

中文翻译：

---

一种内皮抑素-慢病毒（ES-LV）-EPC基因治疗剂，用于抑制氧引起的视网膜病变大鼠模型中的新血管形成。

基因转染的内皮祖细胞（EPC）的移植已为肿瘤新血管形成治疗提供了新方法，但为眼部疾病提供了新方法。这项研究旨在调查内皮抑素转染的EPC在视网膜新血管形成治疗中的功效。定量逆转录聚合酶链反应（qRT-PCR）显示内皮抑素在内皮抑素-慢病毒-EPCs中高表达。内皮抑素-慢病毒和内皮抑素-慢病毒-EPC组的新生血管渗漏面积和视网膜前新生血管细胞核数目均明显减少，这两种治疗对视网膜新生血管形成的抑制作用几乎相同。两组还显示内皮抑素的视网膜分布更大。玻璃体内注射内皮抑素-慢病毒EPCs可抑制视网膜新血管形成，血管内皮生长因子（VEGF）和CD31表达，并在体内增加内皮抑素表达。内皮抑素-慢病毒-EPC靶向并预防病理性视网膜新血管形成。基因组合的EPC代表了一种潜在的新型治疗血管新生疾病的治疗剂。